MX2021002090A - Metodos para reducir el riesgo de diabetes en pacientes que son tratados por enfermedades relacionadas con el colesterol alto. - Google Patents

Metodos para reducir el riesgo de diabetes en pacientes que son tratados por enfermedades relacionadas con el colesterol alto.

Info

Publication number
MX2021002090A
MX2021002090A MX2021002090A MX2021002090A MX2021002090A MX 2021002090 A MX2021002090 A MX 2021002090A MX 2021002090 A MX2021002090 A MX 2021002090A MX 2021002090 A MX2021002090 A MX 2021002090A MX 2021002090 A MX2021002090 A MX 2021002090A
Authority
MX
Mexico
Prior art keywords
methods
diabetes
patients
statin
risk
Prior art date
Application number
MX2021002090A
Other languages
English (en)
Inventor
Narendra Dhanraj Lalwani
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of MX2021002090A publication Critical patent/MX2021002090A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden dosis fijas de ETC-1002, ezetimiba, y estatina, y métodos para tratar sujetos que comprenden administrar dosis fijas de ETC-1002, ezetimiba, y estatina. También se describen en la presente métodos para administrar dosis fijas de ETC-1002 o ezetimiba o ambas a pacientes intolerantes a estatina o pacientes que reciben terapia con estatina, en donde la administración reduce la probabilidad de empeoramiento de diabetes en el sujeto o incrementan la probabilidad de diabetes de nueva aparición en un sujeto. Los métodos descritos en la presente también incluyen métodos para tratar la hipercolesterolemia y enfermedades cardiovasculares en un sujeto.
MX2021002090A 2018-08-24 2019-08-26 Metodos para reducir el riesgo de diabetes en pacientes que son tratados por enfermedades relacionadas con el colesterol alto. MX2021002090A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862722766P 2018-08-24 2018-08-24
US201862751404P 2018-10-26 2018-10-26
PCT/US2019/048184 WO2020041799A1 (en) 2018-08-24 2019-08-26 Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses

Publications (1)

Publication Number Publication Date
MX2021002090A true MX2021002090A (es) 2021-04-28

Family

ID=69591419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002090A MX2021002090A (es) 2018-08-24 2019-08-26 Metodos para reducir el riesgo de diabetes en pacientes que son tratados por enfermedades relacionadas con el colesterol alto.

Country Status (14)

Country Link
US (1) US20210322376A1 (es)
EP (1) EP3841105A4 (es)
JP (2) JP2021534208A (es)
KR (1) KR20210079275A (es)
CN (1) CN113166195A (es)
AU (1) AU2019325705A1 (es)
BR (1) BR112021003265A2 (es)
CA (1) CA3110346A1 (es)
CL (1) CL2021000444A1 (es)
CO (1) CO2021003726A2 (es)
IL (1) IL281016A (es)
MX (1) MX2021002090A (es)
SG (1) SG11202101717WA (es)
WO (1) WO2020041799A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978204A1 (en) 2015-03-13 2016-09-22 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
EP3844168A4 (en) * 2018-08-27 2022-05-18 Esperion Therapeutics, Inc. COMBINATION DRUG PREPARATIONS FOR THE TREATMENT OF PATIENTS WITH CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065670A1 (es) * 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN103239449A (zh) * 2012-12-26 2013-08-14 辽宁亿灵科创生物医药科技有限公司 一种依折麦布、辛伐他汀和烟酸的复方制剂及其制备方法
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
US20210361618A1 (en) * 2017-02-08 2021-11-25 Esperion Therapeutics, Inc. Triplet combination formulations and methods for treating or reducing the risk of cardiovascular disease

Also Published As

Publication number Publication date
JP2024081650A (ja) 2024-06-18
CN113166195A (zh) 2021-07-23
JP2021534208A (ja) 2021-12-09
EP3841105A4 (en) 2022-05-04
IL281016A (en) 2021-04-29
US20210322376A1 (en) 2021-10-21
KR20210079275A (ko) 2021-06-29
AU2019325705A1 (en) 2021-03-18
BR112021003265A2 (pt) 2021-05-18
CO2021003726A2 (es) 2021-07-30
WO2020041799A1 (en) 2020-02-27
CL2021000444A1 (es) 2021-07-02
EP3841105A1 (en) 2021-06-30
CA3110346A1 (en) 2020-02-27
SG11202101717WA (en) 2021-03-30

Similar Documents

Publication Publication Date Title
MX2022004137A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
EP4324521A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
JP2013155188A5 (es)
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
EA201890182A1 (ru) Терапевтическое средство для лечения синдрома гунтера и способ его лечения
EP4316589A3 (en) Treatment of patients with classic fabry disease
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
MX2021002090A (es) Metodos para reducir el riesgo de diabetes en pacientes que son tratados por enfermedades relacionadas con el colesterol alto.
EP3590338A3 (en) Medical treatments based on anamorelin
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
MX2019008076A (es) Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada.
ZA202201446B (en) Methods of treating multifocal cancer
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
EP4327869A3 (en) Methods of treating fabry patients having renal impairment
WO2018231799A8 (en) Methods of treating brain tumors using combination therapy
Streiner Propranolol in schizophrenia